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Abstract Dedicated software packages incorporating
prognostic models are meant to aid physicians in making
accurate predictions of prognosis. This study concerns 742
predictions of 5-year survival on consecutive newly diag-
nosed patients with head- and neck squamous cell carci-
noma. The 5-year survival predictions made by the
physicians are not compared with actual survival, but with
a prediction made by OncologIQ, a dedicated software
package. We used a linear regression and a linear mixed-
effects model to look at absolute differences between both
predictions and possible learning effects. Predictions made
by the physicians were optimistic and inaccurate. Using the
linear regression and linear mixed-effects models, the
physicians’ learning effect showed little improvement per
successive prediction. We conclude that prognostic pre-
dictions in general are imprecise. When given feedback on
the model’s predicted survival, the accuracy increases, but
only very modestly.
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Introduction
Prognostication remains a difﬁcult aspect of daily medicine
and oncology in particular. Due to the uncertainty of future
events, physicians are often unable to give cancer patients
an accurate assessment of their prognosis. This may result
in non-optimal patient counselling and over- and under-
treatment. In oncology the prognosis is classically based on
the TNM-classiﬁcation. However, it is clear that, besides
TNM-classiﬁcation, a variety of covariables play a role in
the prognosis. The combination of factors, however, poses
a difﬁcult equation to the daily practice. Most physicians
will combine their own experience and knowledge on
prognostic factors in order to prognosticate. However, it is
questionable how accurate these assessments are. In 2000,
Christakis and Lamont [1] reported only 20% of predic-
tions done by doctors were to be considered as accurate
(predicted survival within plus or minus 33% of actual
survival). This concerned 343 doctors providing survival
estimates for 468 terminally ill patients admitted to ﬁve
outpatient hospice programmes in Chicago during 130
consecutive days in 1996. The direction of the inaccuracy
of predictions is often to the positive side, doctors are
optimistic on survival prognosis [1–3]. In order to improve
predictions, spreadsheets and dedicated software which
present prognostic models are developed and published in
literature, based on large datasets on which multivariate
survival analyses are done. These programs can help phy-
sicians with patient counselling and deciding on treatment
options. We hypothesise that when the clinical predictions
are supported by such prognostic models, the prediction
error would decrease in time.
The aim of this study is to evaluate the differences
between a 5-year survival prediction done by a physician
on a newly diagnosed head- and neck oncology patient
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We also studied a possible learning effect in the assessment
of the physician if supported by this computerised
prediction.
Materials and methods
This study concerns 742 predictions done by 33 physicians
and the dedicated software package. The average number
of predictions done by individual physicians was 22.5
(range 1–88). All 742 predictions were done on consecu-
tive newly diagnosed patients with head- and neck squa-
mous cell carcinoma, who were discussed in the Leiden
Head and Neck Oncology Cooperative Group. The patient
and tumour characteristics are given in Table 1. All
participating members (otolaryngologists, radiologists,
plastic surgeons, etc.) of the group were asked to make a
5-year survival prediction based on all available patient and
tumour data at hand at that time. Simultaneously, these
data were entered in ‘OncologIQ’, which produces a 5-year
survival prediction as well. We looked at the difference
between these two assessments. After each prediction the
physicians were given the results of the model’s prediction
in order to give them feedback. We must stress that the
predictions made by the physicians are not compared with
actual survival, but with a prediction made by OncologIQ.
OncologIQ is a dedicated software package, which we
presented in 2001 [4].
This program is based on a Cox regression analysis on
1,396 head- and neck oncology patients. This program
takes not only TNM-classiﬁcation into account, but all
available and relevant covariables of survival time in the
Cox regression analysis. The prognostic model consists of
TNM-classiﬁcation, gender, age, localisation of the tumour
and the absence or presence of a prior tumour.
We analysed the data in two different ways. First, we
looked at absolute differences between both predictions
(‘absolute residuals’). The possible decline of these dif-
ferences, as a measure of a possible learning effect, was
analysed using a linear regression model.
Second, we analysed the data with a linear mixed-effects
model [5], in which individual physicians were declared as
random factors in the model. The OncologIQ-score served
as predictor, the physicians’ prediction as outcome and we
used no intercept. This model then simply estimates the
mean physicians’ prediction as a percentage of the Onco-
logIQ prediction. A next step is to add the interaction of the
number of successive predictions per physician and
OncologIQ-score: this leads to the change in percentage
over- or underestimation as a (linear) function of the suc-
cessive predictions per physician. A last step sought is
to differentiate these changes in time between patients
with different characteristics as used to build up the
OncologIQ-score.
For data analysis we used linear regression models in
S-Plus
, version 6.
Results
Figure 1 shows the difference in predictions between the
physician and OncologIQ as a function of successive
predictions. The absolute difference between both predic-
tions is on average 11%, with a range from 0 to 52%. When
Table 1 Baseline characteris-
tics of head- and neck oncology
patient on which the predictions
were made
Shown are the data entered in
OncologIQ
Gender
Male 532
Female 201
Missing 9
Age (years)
\50 89
50–59 230
60–69 274
[70 137
Missing 12
cT-stage
cT1 202
cT2 224
cT3 210
cT4 95
Missing 11
cN-stage
cN0 460
cN1 63
cN2 147
cN3 53
Missing 19
cM-stage
cM0 652
cM1 8
Missing 82
Localisation
Nasopharynx 4
Oral cavity 125
Oropharynx 264
Hypopharynx 72
Larynx glottic 205
Larynx supraglottic 61
Missing 11
Prior malignancies
Yes 85
No 612
Missing 45
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123we consider a difference of B10% (maximum deviation
from 5-year survival prediction made by OncologIQ of
6 months) as accurate, only 277 out of 742 (37.3%)
predictions classify as accurate.
Predictions made by the physicians were optimistically
relative to the OncologIQ’s prediction; 459 out of 742
(61.9%) predictions made by the physicians are in absolute
percentages higher than that of the program (Fig. 1).
The decline in absolute difference between the physi-
cians prediction and that of OncologIQ was 3.6% (95% CI
0.1%, 7.1%) per successive prediction (Fig. 2). In other
words, a learning effect was that the variability between
physicians and OncologIQ decreases with successive
predictions.
Using the linear mixed-effects model (Fig. 3), predic-
tions from physicians were on average 4.5%, too optimistic
(95% CI 2.6, 6.4%). Per successive prediction the differ-
ence between the physicians’ prediction and that of
OncologIQ is declined by 0.1% (p value 0.024). A physi-
cian with more than 45 successive predictions had on
average no optimism in his/her predictions compared to
OncologIQ.
The last step sought is to differentiate changes in time
between patients with different characteristics as used to
build up the OncologIQ-score. This analysis showed no
signiﬁcant interactions (no data shown).
Discussion
Most previous studies on prognostication in oncology
concern the prediction of survival of terminally ill cancer
patients by the physician compared with actual survival
time and relative optimism or pessimism. Chow et al. [2]
examined the accuracy of 739 survival predictions by six
palliative radiation oncologists in 2004. It concerned can-
cer patients with metastatic disease with most common
primary cancer sites being the lung, breast and prostate.
The median survival of the 739 patients was 15.9 weeks.
It showed that the predictions of survival tended to be too
optimistic with a –12.3 weeks difference between the
actual survival and the clinically predicted one. Vigano
et al. [3] showed that in their study the clinical estimation
of survival had a low sensitivity in terminally ill cancer
patients (primary cancer sites: breast, lung, gastrointestinal
and prostate) and a tendency to overestimate survival.
These data concur with those of Christakis and Parkes
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Fig. 1 The difference in predictions between the 5-year survival
predictions made by the physicians and OncologIQ (reference) as a
function of successive predictions. The ﬁtted lines represent the
boundaries of the ‘accurate’ prediction (6 months, 10%)
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Fig. 2 The absolute difference between predictions made by physi-
cian and OncologIQ (‘absolute residuals’) as a function of successive
predictions with a ﬁtted linear regression line
5-year survival prediction made by OncologIQ, in months 
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Fig. 3 The black line represents the beta of the difference in average
predictions (beta 1.045). The dotted red lines represent beta’s for
successive predictions. A physician with just one prediction produces
a beta larger than 1.045, indicating more than average optimism.
A physician with more than 45 successive predictions produces a beta
around 1, indication no optimism
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123[1, 6] who also describe inaccurate and systemically opti-
mistic predictions. Stockler et al. [7] studied the predicted
survival in 102 newly referred patients with incurable
cancer (various primary cancer sites) and found these
predictions to be imprecise (29% were within 0.67–1.33
times the actual survival), but not over optimistic (35%
were[1.33 times the actual survival) or pessimistic (39%
were \0.67 times the actual survival). Median survival
time was 12 months. Muers [8] described 196 consecutive
patients diagnosed and managed as non-small cell lung
cancer, who did not receive curative treatment. Physicians
correctly predicted within 1 month, the survival of only 19
patients (10%). However, almost 59% (115/196) of patients
had their survival predicted to within 3 months. Mackillop
and Quirt [9] asked doctors to estimate the probability of
cure for 98 cancer patients undergoing outpatient treatment
and the duration of survival for 39 incurable patients.
These patients had various primary cancer sites, including
head and neck. In conclusion, the doctors were able to
discriminate quite well between curable and incurable
patients (area under the ROC-curve 0.91), but performed
less when the duration of survival was concerned. Differ-
ences in accuracy and optimism or pessimism between
these studies might be due to differences in primary cancer
sites, mean length of survival and experience of the
physicians. To our knowledge there has been no study
published concerning the prediction of survival comparing
physicians and dedicated software.
At the moment the patients in our study were discussed
at the Head and Neck Oncology Cooperative Group, the
data entered in OncologIQ were probably not exactly the
same as the information available to the physicians. It is
conceivable that some physicians (especially the one who
presents the patient to the other members of the group)
were aware of certain covariables that are not in the
OncologIQ program. Noteworthy is the result presented by
Muers [8], that a prognostic model for prediction of sur-
vival in non-small cell lung cancer patients in which the
physicians’ prediction of survival is incorporated showed
better discriminative performance in comparison with a
model without. This would also suggest that physicians are
not using exactly the same factors as the prognostic model
and must be using additional information. This additional
knowledge, however, does not always have to be beneﬁcial
in prediction making; it could theoretically also blur the
sight on more important prognostic factors.
To our best knowledge there has been no publication in
which the physician’s prediction is compared with that of a
dedicated software program based on a multivariate sur-
vival analysis. In this way we do not compare with actual
outcome (survival time), but with a maximised prediction
based on the knowledge of all relevant covariables at the
time of presentation of these patients. We know from
previous studies that the clinical estimation of survival is
consistently imprecise. That is one of the reasons to
develop these multivariable prognostic models. Our results
show only 37.3% of the predictions to be accurate (maxi-
mum of 10% difference considered as accurate). We
hypothesised that when the clinical prediction was sup-
ported by such a model the prediction error would decrease
in time. This is, however, not that clear cut. In general, we
showed little, but signiﬁcant, improvement in deviation
from the model’s prediction with successive predictions.
We therefore conclude that prognostic predictions in gen-
eral are imprecise. When supported by feedback, the
accuracy increases, but only very modestly. In other words
we do learn, but not spectacularly. In order to maximise the
patient counselling and treatment decision-making we
should rely on a combination of experience and prognostic
models.
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